With Class B holders holding ~99.9% voting power post-proposal, all governance changes will pass; public Class A shareholders face near-total loss of voting influence and heightened dilution risk. Monitor the May 15 vote—if approved, expect potential future equity offerings and a reverse stock split to maintain Nasdaq listing.
Price Chart
Executive Summary
Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive authorized share capital increase (from 500M to 3T shares), a tenfold increase in Class B voting rights (50 to 500 votes/share), and authorization for reverse stock splits up to 1:10,000 to maintain Nasdaq listing. The proposals will further entrench the controlling shareholder—Class A public holders' voting power will drop from 0.9% to 0.1%—and create enormous potential for future dilution. The board recommends all proposals, and with Class B holding 99.1% of votes, passage is virtually certain.
Key Facts
- Authorized share capital proposed to increase from 500M shares (US$0.50 total par) to 3 trillion shares (US$3,000 total par), adding 799.6B Class A, 199.9B Class B, 1T Class C (non-voting), and 1T preference shares.
- Class B voting rights to increase from 50 to 500 votes per share; Class A voting power to fall from ~0.9% to ~0.1% of total.
- Share consolidation authorized at ratios from 2:1 to 10,000:1 to address potential Nasdaq bid price deficiency.
- Class B shares to become convertible into Class A at holder's option (currently not convertible).
- Board recommends all proposals; Class B holders control 99.1% of voting power as of April 22, 2026 record date.
Financial Impact
Authorized share capital increase of 6,000x from 500M to 3T shares with $0 par value, enabling massive future equity issuances without further shareholder approval. Reverse split up to 10,000:1 could drastically reduce share count but also signals potential delisting risk.
Risk Factors
- Massive future equity dilution from newly authorized shares (3T total vs. 144M currently outstanding).
- Reverse stock split could compress liquidity and is often viewed negatively by the market.
- Further entrenchment of controlling shareholder reduces accountability to public holders.
- Potential Nasdaq delisting if bid price compliance is not achieved despite reverse split.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-001504 |
| Document: anbioex99-1.htm | 0001185185-26-001504 |
| Document: anbioex99-3.htm | 0001185185-26-001504 |
| Document: anbioex99-2.htm | 0001185185-26-001504 |
| Document: anbio6k042226.htm | 0001185185-26-001504 |
| Document: 0001185185-26-001504-index-headers.html | 0001185185-26-001504 |
| Document: 0001185185-26-001504-index.html | 0001185185-26-001504 |
| Document: 0001185185-26-001504.txt | 0001185185-26-001504 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 23w ago | 6-K | $32.34 $10.26 | ▼ −68.27% | ▼ −74.56% | $3.71 (−88.51%) |
Apr 27, 2026 26w ago | 6-K | $27.81 $9.74 | ▲ +64.98% | ▲ +68.97% | $3.71 (+86.64%) |
Apr 7, 2026 28w ago | 20-F | $26.94 $12.70 | ▼ −52.86% | ▼ −63.31% | $3.71 (−86.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers